In this episode of This Is Why, Dr. Busti unpacks the pharmacology and clinical relevance of the potassium-competitive acid blocker (P-CAB) class—featuring vonoprazan, the newest option in acid suppression therapy.
You’ll learn how P-CABs compare to H₂ receptor antagonists and proton pump inhibitors (PPIs) in terms of mechanism, onset, and duration of acid control. Dr. Busti explains the unique pharmacodynamic and pharmacokinetic properties that make vonoprazan a valuable alternative for patients who do not adequately respond to PPIs.
The discussion connects the drug’s molecular action at the parietal cell to the anatomy of the gastrointestinal tract, helping you understand why this mechanism matters in conditions such as GERD, H. pylori infection, peptic ulcer disease, and erosive esophagitis. You’ll also explore the potential side effects, electrolyte disturbances, and drug–drug interactions to watch for in clinical practice.
By grounding pharmacology in pathophysiology and anatomy, this episode helps clinicians and trainees alike integrate new therapies into patient care with confidence and context.
Access tables for this episode at https://www.thisiswhy.health/topics/pharmacology-review-potassium-competitive-acid-blockers-pcab
Disclaimer: This content is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard in this content.
